{"id":9626,"date":"2025-09-17T11:40:22","date_gmt":"2025-09-17T09:40:22","guid":{"rendered":"https:\/\/www.ebma-europe.com\/los-origenes-de-la-bigmed\/"},"modified":"2026-03-11T10:11:55","modified_gmt":"2026-03-11T09:11:55","slug":"los-origenes-de-la-bigmed","status":"publish","type":"page","link":"https:\/\/www.ebma-europe.com\/es\/bigmed\/los-origenes-de-la-bigmed\/","title":{"rendered":"Los or\u00edgenes de la BI(G)MED"},"content":{"rendered":"\n
\n
<\/span>
\n\t
\n\t\t\n\n\t
    \n\t\t\t\t\t
  1. \n\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\tInicio\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t<\/ol>\n\n\t<\/nav>\t<\/div>\n\n\n

    \n\tLos or\u00edgenes de la BI(G)MED<\/h1>\n\n\n\n

    A principios de los a\u00f1os 2000, la secuenciaci\u00f3n completa del ADN humano (proyecto \u00abHuman Genome\u00bb<\/a>) pone de manifiesto la importancia de la gen\u00e9tica en el funcionamiento del sistema inmunitario<\/strong>. <\/p>\n\n\n\n

    El Dr. Gilbert Glady, entonces especializado en microinmunoterapia, percibe r\u00e1pidamente todo el potencial de estos descubrimientos.<\/p>\n<\/div><\/div>\n<\/div>\n\n\n\n

    \n

    Los avances cient\u00edficos principales<\/h2>\n\n\n\n
    \n
    \n

    1796<\/strong><\/p>\n\n\n\n

    \n

    Homeopat\u00eda y dosis ultrabajas<\/h3>\n\n\n\n
    \"\"<\/figure>\n<\/div>\n\n\n\n

    Samuel Hahnemann<\/strong><\/a> funda la homeopat\u00eda, introduciendo el principio de las diluciones infinitesimales.<\/p>\n<\/div>\n\n\n\n

    \n

    1869<\/strong><\/p>\n\n\n\n

    \n

    Descubrimiento del ADN<\/h3>\n\n\n\n
    \"\"<\/figure>\n<\/div>\n\n\n\n

    Friedrich Miescher<\/a><\/strong> a\u00edsla una sustancia en los n\u00facleos celulares que denomina \u00abnucle\u00edna\u00bb (posteriormente reconocida como ADN).<\/p>\n<\/div>\n\n\n\n

    \n

    1893<\/strong><\/p>\n\n\n\n

    \n

    Primeros pasos hacia la inmunoterapia<\/h3>\n\n\n\n
    \"\"<\/figure>\n<\/div>\n\n\n\n

    William B. Coley<\/strong><\/a> demuestra que se pueden tratar tumores estimulando el sistema inmunitario.<\/p>\n<\/div>\n\n\n\n

    \n

    1942<\/strong><\/p>\n\n\n\n

    \n

    Descubrimiento de la epigen\u00e9tica<\/h3>\n\n\n\n
    \"\"<\/figure>\n<\/div>\n\n\n\n

    Conrad Hal Waddington<\/a><\/strong> sienta las bases de la modificaci\u00f3n del fenotipo por el entorno sin acci\u00f3n sobre el ADN.<\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

    \n
    \n
    \n

    1953<\/strong><\/p>\n\n\n\n

    \n

    Estructura en doble h\u00e9lice del ADN<\/h3>\n\n\n\n
    \"\"<\/figure>\n<\/div>\n\n\n\n

    James<\/strong> Watson<\/strong><\/a> y Francis Crick<\/a><\/strong> describen la estructura del ADN, bas\u00e1ndose en los datos de Rosalind Franklin.<\/p>\n<\/div>\n\n\n\n

    \n

    1975<\/strong><\/p>\n\n\n\n

    \n

    Anticuerpos monoclonales <\/h3>\n\n\n\n
    \"\"<\/figure>\n<\/div>\n\n\n\n

    Georges K\u00f6hler<\/a> y Cesar Milstein<\/a><\/strong> desarrollan la tecnolog\u00eda de los anticuerpos monoclonales, fundamento de las futuras inmunoterapias.<\/p>\n<\/div>\n\n\n\n

    \n

    1993<\/strong><\/p>\n\n\n\n

    \n

    Descubrimiento de los microARNs (miARN)<\/h3>\n\n\n\n
    \"\"<\/figure>\n<\/div>\n\n\n\n

    Victor Ambros<\/a> y Gary Ruvkun<\/a><\/strong> identifican el primer microARN en el nematodo C. elegans<\/em>, regulando la expresi\u00f3n g\u00e9nica.<\/p>\n<\/div>\n\n\n\n

    \n

    1996<\/strong><\/p>\n\n\n\n

    \n

    Mecanismos epigen\u00e9ticos<\/h3>\n\n\n\n
    \"\"<\/figure>\n<\/div>\n\n\n\n

    Reconocimiento de las modificaciones de histonas y de la metilaci\u00f3n como mecanismos clave de regulaci\u00f3n.<\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

    \n
    \n
    \n

    1998<\/strong><\/p>\n\n\n\n

    \n

    ARN interferente (ARNi)<\/h3>\n\n\n\n
    \"\"<\/figure>\n\n\n\n

    Andrew Fire<\/a> y Craig Mello<\/a><\/strong> descubren que los ARN de doble cadena pueden inhibir espec\u00edficamente la expresi\u00f3n de genes, mecanismo de interferencia ARN.<\/p>\n<\/div>\n<\/div>\n\n\n\n

    \n

    A\u00f1os 2000<\/strong><\/p>\n\n\n\n

    \n

    Investigaciones sobre los ARN no codificantes<\/h3>\n\n\n\n
    \"\"<\/figure>\n<\/div>\n\n\n\n

    Reconocimiento de que la mayor\u00eda del genoma transcribe ARN no codificante: lncRNA, circRNA, piRNA\u2026<\/p>\n<\/div>\n\n\n\n

    \n

    Desde 2010<\/strong><\/p>\n\n\n\n

    \n

    Investigaciones sobre las dosis ultrabajas<\/h3>\n\n\n\n
    \"\"<\/figure>\n<\/div>\n\n\n\n

    Estudios sobre la hormesis, las se\u00f1ales d\u00e9biles, la memoria del agua, las nanoestructuras y los ARN a dosis ultrabajas.<\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

    \n

    De la microinmunoterapia a la BI(G)MED<\/h2>\n\n\n\n
    \n
    \n

    1983-2010<\/strong><\/p>\n\n\n\n

    \"\"<\/figure>\n\n\n\n
    \n

    El Dr. Gilbert Glady<\/a> difunde la microinmunoterapia en Europa<\/strong>, tras haber trabajado junto al Dr. Maurice Jenaer, pionero del uso de las altas diluciones en inmunolog\u00eda.<\/p>\n<\/div>\n<\/div>\n\n\n\n

    \n

    2010<\/strong><\/p>\n\n\n\n

    \"\"<\/figure>\n\n\n\n
    \n

    El Dr. Gilbert Glady<\/a> crea la Medicina Bio Inmuno(G)en\u00e9tica<\/strong> (BI(G)MED), integrando estos descubrimientos para modular mejor la expresi\u00f3n de los genes gracias a los microARNs.<\/p>\n<\/div>\n<\/div>\n\n\n\n

    \n

    2012<\/strong><\/p>\n\n\n\n

    \"\"<\/figure>\n\n\n\n
    \n

    El Dr. Gilbert Glady<\/a> crea la Asociaci\u00f3n Europea de Medicina Bio Inmuno(G)en\u00e9tica<\/strong> EBMA<\/a> para desarrollar y promover la BI(G)MED en Europa.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

    \n

    Gracias a los avances en gen\u00e9tica y epigen\u00e9tica, la BI(G)MED se posiciona como un m\u00e9todo terap\u00e9utico innovador<\/strong>, orientado a modular los mecanismos moleculares e inmunitarios implicados en numerosas patolog\u00edas.<\/p>\n\n\n\n

    Su r\u00e1pida expansi\u00f3n en Europa<\/strong> ilustra el creciente inter\u00e9s por estos enfoques de salud globales y personalizados.<\/p>\n\n\n\n

    Desde la creaci\u00f3n de la BI(G)MED por el Dr. Glady, cientos de terapeutas han sido formados<\/strong> en varios pa\u00edses, especialmente en Francia, B\u00e9lgica, Suiza, Alemania, Austria y Espa\u00f1a. <\/p>\n<\/div>\n\n\n\n

    \n
    \n
    \n
    <\/span>
    \n

    M\u00e1s informaci\u00f3n sobre la BI(G)MED<\/strong><\/h2>\n\n\n\n
    \n
    \u00bfQu\u00e9 es la Medicina Bio Inmuno(G)en\u00e9tica?<\/a><\/div>\n<\/div>\n<\/div><\/div>\n<\/div>\n\n\n\n
    \n
    <\/span>
    \n

    Descubrir las formaciones<\/strong><\/h2>\n\n\n\n
    \n
    Consultar informaci\u00f3n<\/a><\/div>\n<\/div>\n<\/div><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

    <\/p>\n","protected":false},"excerpt":{"rendered":"

    En 2010, el Dr. Glady crea la Medicina Bio Inmuno(G)en\u00e9tica (BI(G)MED), integrando estos descubrimientos en microinmunoterapia para modular mejor la expresi\u00f3n de los genes gracias a los microARNs.<\/p>\n","protected":false},"author":778,"featured_media":0,"parent":9867,"menu_order":10,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-9626","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nDe la microinmunoterapia a la Medicina Bio Inmuno(G)en\u00e9tica | EBMA Europe<\/title>\n<meta name=\"description\" content=\"En 2010, el Dr. Glady cre\u00f3 la Medicina Bio Inmuno(G)en\u00e9tica integrando sus descubrimientos en microinmunoterapia. Descubra todo el contexto hist\u00f3rico.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ebma-europe.com\/es\/bigmed\/los-origenes-de-la-bigmed\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"De la microinmunoterapia a la Medicina Bio Inmuno(G)en\u00e9tica | EBMA Europe\" \/>\n<meta property=\"og:description\" content=\"En 2010, el Dr. Glady cre\u00f3 la Medicina Bio Inmuno(G)en\u00e9tica integrando sus descubrimientos en microinmunoterapia. Descubra todo el contexto hist\u00f3rico.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ebma-europe.com\/es\/bigmed\/los-origenes-de-la-bigmed\/\" \/>\n<meta property=\"og:site_name\" content=\"EBMA Europe\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-11T09:11:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ebma-europe.com\/wp-inside\/uploads\/2026\/01\/1796.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/es\\\/bigmed\\\/los-origenes-de-la-bigmed\\\/\",\"url\":\"https:\\\/\\\/www.ebma-europe.com\\\/es\\\/bigmed\\\/los-origenes-de-la-bigmed\\\/\",\"name\":\"De la microinmunoterapia a la Medicina Bio Inmuno(G)en\u00e9tica | EBMA Europe\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/es\\\/bigmed\\\/los-origenes-de-la-bigmed\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/es\\\/bigmed\\\/los-origenes-de-la-bigmed\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.ebma-europe.com\\\/wp-inside\\\/uploads\\\/2026\\\/01\\\/1796-1024x683.png\",\"datePublished\":\"2025-09-17T09:40:22+00:00\",\"dateModified\":\"2026-03-11T09:11:55+00:00\",\"description\":\"En 2010, el Dr. Glady cre\u00f3 la Medicina Bio Inmuno(G)en\u00e9tica integrando sus descubrimientos en microinmunoterapia. Descubra todo el contexto hist\u00f3rico.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/es\\\/bigmed\\\/los-origenes-de-la-bigmed\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ebma-europe.com\\\/es\\\/bigmed\\\/los-origenes-de-la-bigmed\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/es\\\/bigmed\\\/los-origenes-de-la-bigmed\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.ebma-europe.com\\\/wp-inside\\\/uploads\\\/2026\\\/01\\\/1796-1024x683.png\",\"contentUrl\":\"https:\\\/\\\/www.ebma-europe.com\\\/wp-inside\\\/uploads\\\/2026\\\/01\\\/1796-1024x683.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/es\\\/bigmed\\\/los-origenes-de-la-bigmed\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inicio\",\"item\":\"https:\\\/\\\/www.ebma-europe.com\\\/es\\\/inicio\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BI(G)MED\",\"item\":\"https:\\\/\\\/www.ebma-europe.com\\\/es\\\/bigmed\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Los or\u00edgenes de la BI(G)MED\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.ebma-europe.com\\\/es\\\/\",\"name\":\"EBMA Europe\",\"description\":\"European Bio Immune(G)ene Medicine Association\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/es\\\/#organization\"},\"alternateName\":\"EBMA\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ebma-europe.com\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/es\\\/#organization\",\"name\":\"EBMA Europe\",\"alternateName\":\"EBMA\",\"url\":\"https:\\\/\\\/www.ebma-europe.com\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ebma-europe.com\\\/wp-inside\\\/uploads\\\/2026\\\/03\\\/enity-logo-ebma.png\",\"contentUrl\":\"https:\\\/\\\/www.ebma-europe.com\\\/wp-inside\\\/uploads\\\/2026\\\/03\\\/enity-logo-ebma.png\",\"width\":696,\"height\":696,\"caption\":\"EBMA Europe\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ebma-europe.com\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/fr.linkedin.com\\\/company\\\/ebma-europe\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"De la microinmunoterapia a la Medicina Bio Inmuno(G)en\u00e9tica | EBMA Europe","description":"En 2010, el Dr. Glady cre\u00f3 la Medicina Bio Inmuno(G)en\u00e9tica integrando sus descubrimientos en microinmunoterapia. Descubra todo el contexto hist\u00f3rico.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ebma-europe.com\/es\/bigmed\/los-origenes-de-la-bigmed\/","og_locale":"es_ES","og_type":"article","og_title":"De la microinmunoterapia a la Medicina Bio Inmuno(G)en\u00e9tica | EBMA Europe","og_description":"En 2010, el Dr. Glady cre\u00f3 la Medicina Bio Inmuno(G)en\u00e9tica integrando sus descubrimientos en microinmunoterapia. Descubra todo el contexto hist\u00f3rico.","og_url":"https:\/\/www.ebma-europe.com\/es\/bigmed\/los-origenes-de-la-bigmed\/","og_site_name":"EBMA Europe","article_modified_time":"2026-03-11T09:11:55+00:00","og_image":[{"width":1536,"height":1024,"url":"https:\/\/www.ebma-europe.com\/wp-inside\/uploads\/2026\/01\/1796.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"6 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ebma-europe.com\/es\/bigmed\/los-origenes-de-la-bigmed\/","url":"https:\/\/www.ebma-europe.com\/es\/bigmed\/los-origenes-de-la-bigmed\/","name":"De la microinmunoterapia a la Medicina Bio Inmuno(G)en\u00e9tica | EBMA Europe","isPartOf":{"@id":"https:\/\/www.ebma-europe.com\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ebma-europe.com\/es\/bigmed\/los-origenes-de-la-bigmed\/#primaryimage"},"image":{"@id":"https:\/\/www.ebma-europe.com\/es\/bigmed\/los-origenes-de-la-bigmed\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ebma-europe.com\/wp-inside\/uploads\/2026\/01\/1796-1024x683.png","datePublished":"2025-09-17T09:40:22+00:00","dateModified":"2026-03-11T09:11:55+00:00","description":"En 2010, el Dr. Glady cre\u00f3 la Medicina Bio Inmuno(G)en\u00e9tica integrando sus descubrimientos en microinmunoterapia. Descubra todo el contexto hist\u00f3rico.","breadcrumb":{"@id":"https:\/\/www.ebma-europe.com\/es\/bigmed\/los-origenes-de-la-bigmed\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ebma-europe.com\/es\/bigmed\/los-origenes-de-la-bigmed\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.ebma-europe.com\/es\/bigmed\/los-origenes-de-la-bigmed\/#primaryimage","url":"https:\/\/www.ebma-europe.com\/wp-inside\/uploads\/2026\/01\/1796-1024x683.png","contentUrl":"https:\/\/www.ebma-europe.com\/wp-inside\/uploads\/2026\/01\/1796-1024x683.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ebma-europe.com\/es\/bigmed\/los-origenes-de-la-bigmed\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inicio","item":"https:\/\/www.ebma-europe.com\/es\/inicio\/"},{"@type":"ListItem","position":2,"name":"BI(G)MED","item":"https:\/\/www.ebma-europe.com\/es\/bigmed\/"},{"@type":"ListItem","position":3,"name":"Los or\u00edgenes de la BI(G)MED"}]},{"@type":"WebSite","@id":"https:\/\/www.ebma-europe.com\/es\/#website","url":"https:\/\/www.ebma-europe.com\/es\/","name":"EBMA Europe","description":"European Bio Immune(G)ene Medicine Association","publisher":{"@id":"https:\/\/www.ebma-europe.com\/es\/#organization"},"alternateName":"EBMA","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ebma-europe.com\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.ebma-europe.com\/es\/#organization","name":"EBMA Europe","alternateName":"EBMA","url":"https:\/\/www.ebma-europe.com\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.ebma-europe.com\/es\/#\/schema\/logo\/image\/","url":"https:\/\/www.ebma-europe.com\/wp-inside\/uploads\/2026\/03\/enity-logo-ebma.png","contentUrl":"https:\/\/www.ebma-europe.com\/wp-inside\/uploads\/2026\/03\/enity-logo-ebma.png","width":696,"height":696,"caption":"EBMA Europe"},"image":{"@id":"https:\/\/www.ebma-europe.com\/es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/fr.linkedin.com\/company\/ebma-europe"]}]}},"_links":{"self":[{"href":"https:\/\/www.ebma-europe.com\/es\/wp-json\/wp\/v2\/pages\/9626","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ebma-europe.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ebma-europe.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ebma-europe.com\/es\/wp-json\/wp\/v2\/users\/778"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ebma-europe.com\/es\/wp-json\/wp\/v2\/comments?post=9626"}],"version-history":[{"count":10,"href":"https:\/\/www.ebma-europe.com\/es\/wp-json\/wp\/v2\/pages\/9626\/revisions"}],"predecessor-version":[{"id":13182,"href":"https:\/\/www.ebma-europe.com\/es\/wp-json\/wp\/v2\/pages\/9626\/revisions\/13182"}],"up":[{"embeddable":true,"href":"https:\/\/www.ebma-europe.com\/es\/wp-json\/wp\/v2\/pages\/9867"}],"wp:attachment":[{"href":"https:\/\/www.ebma-europe.com\/es\/wp-json\/wp\/v2\/media?parent=9626"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}